To determine the pivotal role of ALDH1 activity in mediating AURKA-induced self-renewal capacity, tertiary SUM-149PT MPS were treated with the potent ALDH1 inhibitor A37 for 8 days. Here, ALDH1A1 is linked to mucopolysaccharidosis.